The DOI matches its Crossref record; 339 of the 343 references it cites were found in a registry or an index.
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Abstract
Hormone therapy (HT) is an effective treatment for menopausal symptoms, including vasomotor symptoms and genitourinary syndrome of menopause. Randomized trials also demonstrate positive effects on bone health, and age-stratified analyses indicate more favorable effects on coronary heart disease and all-cause mortality in younger women (close proximity to menopause) than in women more than a decade past menopause. In the absence of contraindications or other major comorbidities, recently menopausal women with moderate or severe symptoms are appropriate candidates for HT. The Women’s Health Initiative (WHI) hormone therapy trials—estrogen and progestin trial and the estrogen-alone trial—clarified the benefits and risks of HT, including how the results differed by age. A key lesson from the WHI trials, which was unfortunately lost in the posttrial cacophony, was that the risk:benefit ratio and safety profile of HT differed markedly by clinical characteristics of the participants, especially age, time since menopause, and comorbidity status. In the present review of the WHI and other recent HT trials, we aim to provide readers with an improved understanding of the importance of the timing of HT initiation, type and route of administration, and of patient-specific considerations that should be weighed when prescribing HT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although estrogen replacement therapy (or hormone replacement therapy) can effectively manage menopause symptoms and post-menopausal osteoporosis, its benefits must be weighed against the heightened risks of blood clots, stroke, and breast cancer, especially with long-term use [50, 51].”
In the citing paper
“The balance of risks and benefits associated with hormone replacement therapy varies considerably based on individual physiology, time since menopause onset, and the specific type of hormone replacement therapy [50].”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
The Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,119
Breast cancer and hormone-replacement therapy in the Million Women Study
Beral, V. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,986
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
Calle, E. E., Heath Jr., C. W., Coates, R. J., Liff, J. M., Franceschi, S., Talamini, R., Chantarakul, N., Koetsawang, S., Rachawat, D., Morabia, A., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)08233-0 · Cited by 2,450
Research works printed but not linked: 4
- Taylor, 2019, Reproductive aging, menopause transition, and menopause hormone therapy
- Pinkerton, 2013, Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial, Obstet Gynecol, 121, 959, 10.1097/AOG.0b013e31828c5974 · DOI
- NICE Guidelines (NG23), Menopause: diagnosis and management
- Manson, 2018, Chapter 388: Menopause and postmenopausal hormone therapy
Cited by
Sorted by citations
Kim, J., & Münster, P. N. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.824 · Cited by 134
Hormone therapy regimens for managing the menopause and premature ovarian insufficiency
Armeni, E., Paschou, S. Α., Goulis, D. G., & Lambrinoudaki, I. V. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101561 · Cited by 116
Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society
Lambrinoudaki, I. V., Armeni, E., Goulis, D. G., Bretz, S., Ceauşu, I., Durmuşoğlu, F., Erkkola, R., Fistonić, I., Gambacciani, M., Geukes, M., et al. (2022) · Maturitas · doi:10.1016/j.maturitas.2022.04.008 · Cited by 110
Ye, C., Ebeling, P. R., & Kline, G. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01385-6 · Cited by 99
Gut microbiota has the potential to improve health of menopausal women by regulating estrogen
Wang, H., Shi, F., Zheng, L., Zhou, W., Mi, B., Wu, S., & Feng, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1562332 · Cited by 47
Metadata
- Authors
- Flores, V. A., Pal, L., & Manson, J. E.
- Affiliations
- Yale University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Flores, Valerie A
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2021-04-15
- Volume
- 42
- Issue
- 6
- Pages
- 720-752
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W3155312871
- Cited by
- 174
- References
- 343
- Citations by year
- 2026: 40 · 2025: 45 · 2024: 44 · 2023: 30 · 2022: 13 · 2021: 2
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- hormone therapy, menopause, vasomotor symptoms, genitourinary syndrome of menopause, bone health, coronary artery disease, all-cause mortality, Women's Health Initiative, estrogen-progestin, estrogen-only therapy, timing of hormone therapy initiation, route of administration, risk-benefit assessment
- MeSH terms
- Estrogens, Female, Humans, Menopause, Estrogen Replacement Therapy, Women's Health, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
